INTRODUCTION {#j_jtim-2019-0031_s_001}
============

Adequate antimicrobial therapy is essential to maximize the survival of critically ill patients.^\[[@j_jtim-2019-0031_ref_001]\]^ Anti-infective drugs are classified as time-dependent (*e.g.*, β-lactams, carbapenems, macrolides, fluconazole, vancomycin) when their bactericidal effect depends on the time that plasma levels remain above a threshold minimal inhibitory concentration (MIC), or concentration-dependent (*e.g.*, aminoglycosides, fluoroquinolones, echinocandins, daptomycin, polyenes, doxycyclin) when the height of peak concentration above the MIC determines the killing effect.^\[[@j_jtim-2019-0031_ref_002]\]^ Acute kidney injury (AKI) significantly interferes with the administration of anti-infective agents. Antibacterial pharmacokinetics (PK) are affected by AKI itself, the underlying or accompanying disease process, and the applied renal replacement therapy. Continuous renal replacement therapy (CRRT) causes alterations in drug clearance. Factors influencing PK and pharmacodynamics (PD) of antimicrobial drugs during CRRT include the CRRT mode (diffusion, convection, or both), changes in blood and ultrafiltration flow, type of filtration membrane (*e.g.*, highly adsorptive filters), and discrepancies between prescribed and actually administered antimicrobial dose. For these reasons, drug dose adjustment in critically ill patients receiving CRRT is challenging.^\[[@j_jtim-2019-0031_ref_003],[@j_jtim-2019-0031_ref_004],[@j_jtim-2019-0031_ref_005]\]^

Continuous veno-venous hemofiltration (CVVH) is the most commonly used CRRT technique in the critical care setting.^\[[@j_jtim-2019-0031_ref_005]\]^ Antimicrobial drug behavior during CVVH is still scarcely documented. This is of concern because higher ultrafiltrate doses are increasingly promoted.^\[[@j_jtim-2019-0031_ref_007],[@j_jtim-2019-0031_ref_008],[@j_jtim-2019-0031_ref_009]\]^. Moreover, great divergence exist between predicted and observed removal of antibiotics in critically ill CVVH-treated patients.^\[[@j_jtim-2019-0031_ref_010]\]^

We applied the established PK/PD principles in a subgroup of patients from the previously published IVOIRE trial, which compared high volume (HV; 70 mL/kg/h) with standard volume (SV; 35 mL/kg/h) CVVH in septic shock patients with AKI.^\[[@j_jtim-2019-0031_ref_011]\]^ Importantly, the IVOIRE trial was conceived in 2004 when PK/PD knowledge was still in its infancy. At that time, no consensus existed regarding antimicrobial dosing during HV-CVVH. Also, the primary endpoint of the IVOIRE study was comparing the 28-day mortality between the patients treated with HV-CVVH and SV-CVVH. Therefore, upfront use of higher antimicrobial doses in the HV-CVVH group was not supported because it was thought to produce substantial outcome bias. It was decided to administer all drugs according to the accepted dose recommendations at that time (*i.e.*, weight-adapted, as in patients without AKI) and to treat both SV-CVVH and HV-CVVH patients with comparable doses of antimicrobials either in continuous or intermittent infusion.

The current study is aimed to assess whether a different convection rate determines antimicrobial PK behavior during CVVH. The study results also allowed to create dose recommendations for some of the most commonly used antimicrobials in critically ill patients receiving a CVVH dose of at least 25 mL/kg/h.

PATIENTS AND METHODS {#j_jtim-2019-0031_s_002}
====================

Patients {#j_jtim-2019-0031_s_002_s_001}
--------

PK/PD parameters of all administered antimicrobial agents were evaluated in a subgroup of patients who completed a 96 h therapy within the scope of the IVOIRE study. All observations were made abiding the standard routine patient care incorporated within the IVOIRE study protocol.^\[[@j_jtim-2019-0031_ref_011]\]^ The Institutional Ethical Committee waived a formal approval procedure.

Hemofiltration Technique {#j_jtim-2019-0031_s_002_s_002}
------------------------

A 14F coaxial double lumen hemofiltration catheter was inserted either in the right internal jugular vein or in the femoral veins. CVVH was performed using an Aquarius^®^ hemofiltration circuit (Edwards Life Sciences), with a 1.9 m^2^ Aquamax^®^ polyethersulfone filter (Edwards Life Sciences). Since this filter is non-adsorptive, antibiotic elimination is determined by ultrafiltration alone. Hemofiltration treatment was initiated according to randomization towards either SVCVVH or HV-CVVH. Blood flow rate was adapted to obtain a filtration fraction ≤ 25%. Anticoagulation was ensured by non-fractionated heparin. Filters were changed every 48 h or in case of early clotting. Substitution was divided in a 1/3--2/3 proportion between pre- and post-dilution. Patients who still required CVVH at the end of the study were continued on standard hemofiltration at 35 mL/kg/h.

Sample collection {#j_jtim-2019-0031_s_002_s_003}
-----------------

Mass-transfer concept was used to evaluate the concentration of cleared and absorbed antimicrobials. Indicative samples were taken after 12 or 24 h PK steady-state. Five samples were collected in both groups (at H1 \[*i.e.*, 1 h after antimicrobial infusion\], H3, H6, H9 and at H12 or H24). Three samples were taken for each time period, one from the venous line after the filter, one from the effluent bag and one from the patient's arterial catheter. As predilution was used, sampling before the filter was not applied. Time and total effluent volume in the bags were recorded for each sample. All plasma and ultrafiltrate samples were placed in 5 ml Vacutainer tubes and immediately centrifuged and frozen at −80°C until assayed.

Sample assays {#j_jtim-2019-0031_s_002_s_004}
-------------

Plasma and ultrafiltrate concentrations of anti-infective agents were determined with reversed-phase high-performance liquid chromatography (HPLC) using an adapted ultraviolet (UV) detection method.^\[[@j_jtim-2019-0031_ref_013],[@j_jtim-2019-0031_ref_014],[@j_jtim-2019-0031_ref_015]\]^ Plasma samples were extracted by **SPE**? with Phenomenex Strata-X™ or Varian Plexa™ cartridges (for azoles) or ultra-filtered with Microcon™ devices. Dialysate/ultrafiltrate samples underwent no extraction but were directly injected into the system. Chromatographic separation was performed on Prontosil AQ+ 150 x 4.6 mm 5 µm columns (Bischoff), or on a Gemini C6-phenyl 150 × 4.6 mm 5 µm column (Phenomenex) for azoles. Mobile phases used phosphate buffers (at pH between 3.5 and 7) and acetonitrile. TEA 0.04% at pH 2.7 replaced phosphate buffer for piperacilline/tazobactam and ofloxacin. Wavelengths between 210 and 320 nm were used for UV detection. All HPLC methods were validated according to bioanalytical FDA criteria.^\[[@j_jtim-2019-0031_ref_016]\]^ Linezolid, imipenem, and ertapenem were used as an internal standard. Coefficients of determination (*r*^2^) for the plasma assays over the standard curves concentration ranges were all above 0.99 with intercept close to zero for all studies. Within- and between-day coefficients of variation (CV) for plasma samples ranged respectively from 0.84% to 2.52% and from 1.36% to 5.43% at the chosen quality control concentrations. Coefficients of variation (*r*^2^) for the ultrafiltrate assays over the standard curves concentration ranges were all above 0.99 and intercept close to zero for all studies. Here, within- and between-day CV for ultrafiltrate samples ranged respectively from 0.78% to 2.43% and from 1.08% to 4.86% at the chosen quality control concentrations. Within- and between-day accuracy for the plasma and ultrafiltrate assays ranged respectively from 96.23% to 104.32% and from 98.24% to 102.68%. All assays had good sensitivity. *Limit of detection* (LOD) and limit of quantification (LOQ) were under minimal concentrations measured on patients. All HPLC assay parameters are summarized in [Table 2](#j_jtim-2019-0031_tab_002){ref-type="table"}.

Pharmacokinetic analysis {#j_jtim-2019-0031_s_002_s_005}
------------------------

Plasma concentration-time data for all anti-infective agents were analyzed by standard PK methods using Kinetica™ software and an open one-compartmental model with first order elimination (Kinetica™ version 4.4 for Windows, San Diego, CA). Pre-membrane plasma drug concentrations were used to determine the PK parameters. The apparent terminal elimination rate constant (*k*~el~) was assessed by least-squares regression analysis of the terminal portion of the natural log concentration-time curve. Elimination half-life (*t*~1/2~) was calculated as 0.693/*k*~el~. Maximum plasma drug concentration (*C*~max~) was obtained at the end of the drug infusion. Minimum plasma concentration (*C*~min~) was determined by direct measurement at the end of the dosing interval. Steady-state concentration (C~ss~) was determined at PK steady-state during continuous infusion. The area under the concentration-time curve from time zero to the end of the dosing interval (AUC~0-τ~) was calculated by the linear trapezoidal summation method. Since true PK steady-state conditions could not be assumed in all patients, volume of distribution (*V*~d~) was calculated by non-steady-state methods, which take into account the number of doses previously administered. Total systemic clearance (CL~S~) was calculated by dose/AUC~0-τ~. During CVVH, drugs are predominantly cleared by convection but also in part by membrane adsorption. The sieving coefficient (Sc), the drug concentration in ultrafiltrate, was calculated as 2 × *C*~uf~/(*C*~a~ + *C*~v~), where *C*~uf~ is the drug concentration in ultrafiltrate, *C*~a~ -- the drug concentration in pre-membrane plasma (*i.e.*, plasma obtained from the arterial line in predilution), and *C*~v~ -- the drug concentration in post-membrane plasma. Clearance of drug across the membrane during CVVH (CL~CVVH~) was calculated by C~S~ × *Q*~uf~ x dilution factor (dilution factor = blood flow (Qb) / (Qb + predilution flow (Qs pre) with Qs pre = volume infused in predilution). The percentage of CL~S~ attributed to CL~CVVH~ (%CL~S~) is calculated as (CL~CVVH~/CL~S~) × 100. Non-renal clearance (CL~NR~), which is mainly the residual renal and hepatic clearance, was calculated as CL~S~ - CL~CVVH~ as urine output in the study population was negligible. All calculations were made by programming PK and CVVH clearance equations into Microsoft Excel 2003 (Microsoft Corporation, Redmond, WA) spreadsheets. Using Excel, measures of central tendency and variability were evaluated for all patient and CVVH characteristics, PK parameters, and CVVH clearance. European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used to define micro-organism resistance.

PK/PD analysis {#j_jtim-2019-0031_s_002_s_006}
--------------

General PK/PD principles were considered and their clinical application and dosing implications for critically ill patients addressed. The time during which plasma concentrations of free drug are above the minimal inhibitory concentration (MIC) of the infecting pathogen (T \> MIC) was then calculated as natural log (maximum bacterial population size. (*Cfu*~max~) /*C*~MIC~)/*k*~el~, where *C*~MIC~ is the MIC for the organism. The percent *T*% \> MIC was determined by (*T* \> MIC/τ) × 100, where τ is the dosing interval. Target goal for *T*% \> MIC was \> 40 to 50% for clinical efficacy and prevention of resistance. The inhibitory quotient (IQ) corresponding to the C~max~/MIC ratio and the inhibitory area under the curve (AUIC) corresponding to the AUC/MIC ratio were calculated. Target goals for IQ and AUIC were \> 4 and \> 125 respectively for clinical efficacy and prevention of resistance especially for Gram-negative organisms and for concentration-dependent antibiotics. MICs of antibiotics for isolated pathogens were determined by the local clinical microbiology laboratory. Predicted *T*% \> MIC for dosing regimens not observed in the study patients were calculated based on PK parameters derived from the individual patients within both CVVH groups.

Statistical analysis {#j_jtim-2019-0031_s_002_s_007}
--------------------

Differences between demographic variables among patients receiving either HV- or SV-CVVH were assessed by oneway analysis of variance fixed-effects model for continuous variables or by two-way chi-square test for categorical variables. Differences among calculated PK parameters were assessed by the two-tailed Mann-Whitney rank sum test for unpaired non-parametric data. Correlations between PK variables were determined using the Spearman's rank correlation coefficient for non-parametric data. All statistical tests were performed with the Statistica™ version 6.1 for Windows (Statistica™ Software, San Diego, CA). *P* values ≤ 0.05 were considered to be significant.

RESULTS {#j_jtim-2019-0031_s_003}
=======

Forty-five patients were studied for four consecutive days. During this study period, 5 patients received one, 34 patients received two, and 6 patients received three antimicrobial agents. Characteristics of the patients are shown in [Table 1](#j_jtim-2019-0031_tab_001){ref-type="table"}. Two patients died in the first few hours of treatment and the samples of one patient were damaged during transportation. Thus, 42 patients were evaluable. Mean arterial plasma and effluent concentrations of the anti-infective agents in both CVVH groups are illustrated in [Figure 1](#j_jtim-2019-0031_fig_001){ref-type="fig"}. The PK parameters are presented in [Tables 3](#j_jtim-2019-0031_tab_003a){ref-type="table"} and 3 bis. All agents were easily filtered. Mean Sc ranged from 38.70% to 96.70%. Mean t1/2 of all agents during HVCVVH (from 1.29 to 28.54 h) was significantly shorter than during SV CVVH (from 1.51 to 33.85 h) (*P* \< 0.05). CLs, CL~CVVH~, and CL~NR~ of all agents were significantly higher during HV-CVVH than during SV-CVVH (*P* \< 0.05). Renal excretion of all agents ranged between 13% and 100% and 9% and 57% for respectively HV- and SV-CVVH. Drug removal was moderate with SV-CVVH but became significantly enhanced by HV-CVVH due to increased ultrafiltrate flow. Drug half-live was extended, probably because of a sepsis-induced Vd increase in most patients. Irrespective of the antimicrobial agent, PK parameters were similar to those observed in infected patients without impaired renal function. The PK/PD parameters ([Table 4](#j_jtim-2019-0031_tab_004){ref-type="table"}) demonstrated that treatments met efficiency targets for T% \> MIC and IQ. Finally, a significant correlation existed between Quf and CL~S~ (Spearman test: *P* \< 0.005) and between CL~CVVH~ and elimination half-life (Spearman test: *P* \< 0.005).

###### 

Evolution of arterial plasma concentrations and effluent versus time for anti-infective agents in IVOIRE study during high volume CVVH (HD) and standard volume CVVH (BD)

![](jtim-07-155-g001a)

![](jtim-07-155-g001b)

###### 

Demographic characteristics

  **Demographic data**          **All**       **HV**        **LV**
  ----------------------------- ------------- ------------- ------------
  Age (years)                   66 ± 12       69 ± 9        63 ± 14
  Height (cm)                   169 ± 10      170 ± 8       167± 12
  Weight (kg)                   75 ± 18       77± 22        73 ± 13
  Gender (M/F)                  28/14         15/7          13/7
  SAPS 2                        63 ± 10       65 ± 8        61 ± 12
  SOFA                          12 ± 2        12 ± 2        12 ± 2
  Protein                       45 ± 8        45 ± 8        46 ± 9
  Albumin                       21 ± 4        21 ± 4        22 ± 3
  Creatinine                    243 ± 116     278 ± 128     196 ± 82
  Pathology                     42            22            20
    Peritonitis                 26            15            11
    Sepsis                      3             1             2
    Mediastinitis               4             2             2
    Pneumonia                   4             1             3
    Endocarditis                5             3             2
  Urine output (24 h)           223 ± 167     195 ± 166     253 ± 167
  Blood flow rate (mL/min)      278 ± 51      317 ± 37      234 ± 18
  Ultrafiltration rate (mL/h)   3956 ± 1602   5221 ± 1137   2557 ± 433
  28-day mortality              15            8             7

HV: High volume; LV: Low volume.

###### 

HPLC assays parameters.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                 **Column**         **Mobile phase**   **λ (nm)**   **Plasma extraction**   **LOD (µg/mL)**   **LOQ (µg/mL)**   **Volume injected (µL)**
  ------------------------------ ------------------ ------------------ ------------ ----------------------- ----------------- ----------------- --------------------------
  **Ertapenem**                  Prontosil AQ+      Na~2~HPO~4~\       305          Ultrafiltration\        0.05              0.25              40
                                                    pH = 6.5/ACN v/v                Microcon YM10™                                              

  **Imipenem**                   Prontosil AQ+      Na~2~HPO~4~\       305          Ultrafiltration\        0.04              0.20              40
                                                    pH = 6.5/ACN v/v                Microcon YM10™                                              

  **Doripenem**                  Prontosil AQ+      Na~2~HPO~4~\       305          Ultrafiltration\        0.05              0.25              40
                                                    pH = 6.5/ACN v/v                Microcon YM10™                                              

  **Ceftriaxone**                Prontosil AQ+      Na~2~HPO~4~\       272          SPE\                    0.05              0.25              20
                                                    pH = 7/ACN v/v                  Strata-X™                                                   

  **Piperacilline/Tazobactam**   Prontosil AQ+      TEA 0,04%\         210          SPE\                    0.15              0.50              10
                                                    pH = 2.7/ACN v/v                Strata-X™                                                   

  **Ofloxacine**                 Prontosil AQ+      TEA 0,04%\         295          SPE\                    0.03              0.15              20
                                                    pH = 2.7/ACN v/v                Strata-X™                                                   

  **Linezolid**                  Prontosil AQ+      KH~2~PO~4~\        255          SPE\                    0.25              0.75              20
                                                    pH = 3.5/ACN v/v                Strata-X™                                                   

  **Daptomycine**                Prontosil AQ+      Na~2~HPO~4~\       210          SPE\                    0.15              0.50              20
                                                    pH = 5.5/ACN v/v                Strata-X™                                                   

  **Metronidazole**              Prontosil AQ+      Na~2~HPO~4~\       320          SPE\                    0.04              0.20              20
                                                    pH = 7/ACN v/v                  Strata-X™                                                   

  **Fluconazole**                Gemini C6-phenyl   Na~2~HPO~4~\       260          SPE\                    0.02              0.05              25
                                                    pH = 7/ACN v/v                  Varian Plexa™                                               

  **Voriconazole**               Gemini C6-phenyl   Na~2~HPO~4~\       260          SPE\                    0.02              0.05              25
                                                    pH = 7/ACN v/v                  Varian Plexa™                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SPE: Solid phase extraction; ACN: acetonitrile; λ = wavelength; LOD: limit of detection; LOQ: limit of quantification.

###### 

Pharmacokinetic parameters for all studied antimicrobials

  **Parameters (mean)**                   ***n***   **Dose (mg)**   ***τ* (h)**   **C~max~ (µg/mL)**   **C~min~ (µg/mL)**   **C~ss~ (µg/mL)**   **AUC~0-τ~ (µg.h/mL)**   **V~d~ (L)**   **T~1/2~ elimination (h)**
  --------------------------------------- --------- --------------- ------------- -------------------- -------------------- ------------------- ------------------------ -------------- ----------------------------
  Ertapenem HD                            5         1000            24            17.28                5.75                 \-                  181.90                   35             4.41
  Ertapenem BD                            2         1000            24            32.39                17.86                \-                  327.23                   30             6.79
  Imipenem HD Intermittent infusion       4         500             6             13.00                2.10                 \-                  144.88                   25.60          1.29
  Imipenem BD Intermittent infusion       4         500             6             15.30                3.35                 \-                  209.88                   20.70          1.51
  Imipenem HD Continuous infusion         2         2000            24            1.43 (D\*)           0.78 (D\*)           2.74                \-                       \-             \-
  Imipenem BD Continuous infusion         5         2000            24            4.96 (D\*)           2.33 (D\*)           7.19                \-                       \-             \-
  Doripenem HD                            3         500             8             10.16                4.29                 \-                  65.56                    33.67          2.59
  Doripenem BD                            7         500             8             12.82                5.62                 \-                  80.98                    52.61          4.21
  Ceftriaxone HD                          2         2000            24            225.62               5.16                 \-                  235.32                   51.32          4.19
  Ceftriaxone BD                          4         2000            24            283.65               6.85                 \-                  415.37                   40.13          5.76
  Piperacillin HD Intermittent infusion   5         4000            6             145.62               35.56                \-                  122.52                   38.29          3.61
  Piperacillin BD Intermittent infusion   2         4000            6             78.35                39.82                \-                  147.63                   50.99          3.99
  Piperacillin HD Continuous infusion     10        16000           24            91.62 (D\*)          66.38 (D\*)          158.71              90.47                    \-             \-
  Piperacillin BD Continuous infusion     9         16000           24            147.04 (D\*)         109.76 (D\*)         256.54              42.74                    \-             \-
  Ofloxacin HD                            14        200             12            8.47                 3.38                 \-                  64.73                    32.54          6.58
  Ofloxacin BD                            8         200             12            8.77                 2.44                 \-                  52.02                    51.46          8.72
  Linezolid HD                            2         600             12            17.55                6.68                 \-                  129.63                   46.76          6.33
  Linezolid BD                            3         600             12            21.50                4.30                 \-                  131.31                   30.70          4.59
  Daptomycin HD                           4         6 mg/kg         24            55.22                7.53                 \-                  477.72                   20.26          8.53
  Daptomycin BD                           7         6 mg/kg         24            54.93                10.91                \-                  510.99                   17.70          11.94
  Metronidazole HD                        12        500             8             15.97                10.61                \-                  262.57                   42             8.22
  Metronidazole BD                        12        500             8             18.63                10.72                \-                  236.17                   54             10.18
  Fluconazole HD                          2         400             12            17.40                9.10                 \-                  114.39                   73.38          28.54
  Fluconazole BD                          1         400             12            14.60                7.60                 \-                  96.44                    103.71         33.85
  Voriconazole BD                         3         3 mg/kg         12            7.37                 4.79                 \-                  55.00                    65.55          7.19

V~d~ = CL~s~/K~el~; K~el~ = Ln2/T~1/2Kel~; T~1/2Kel~ = elimination half-life; D\* = loading dose; V~d~ = volume of distribution; T~1/2~ = elimination half-life; τ = time interval between two administrations; C~max~ = maximum arterial concentration at the end of infusion; C~min~ = trough arterial concentration; C~ss~ = the steady-state arterial concentration for continuous infusion; AUC~0-τ~ = area under the curve for plasma concentrations between 0 and τ; *n* = number of patients.

###### 

IVOIRE mean pharmacokinetic parameters during CVVH

  **Paramètres (moyenne)**                **CL~s~ (mL/min)**   **C~s~ (%)**   **QUF (mL/min)**   **Dilution factor (%)**   **CL~CVVH~ (mL/min)**   **CL~CVVH~/CL~s~ (%)**   **CL~NR~ (mL/min)**
  --------------------------------------- -------------------- -------------- ------------------ ------------------------- ----------------------- ------------------------ ---------------------
  Ertapenem HD                            91.63                55.90          95.83              77                        41.50                   45                       50.13
  Ertapenem BD                            50.93                38.70          42.67              84                        13.93                   27                       37
  Imipenem HD Intermittent infusion       230.08               66.90          75.83              80                        40.58                   18                       189.50
  Imipenem BD Intermittent infusion       158.82               71.60          32.50              86                        20.01                   13                       138.80
  Imipenem HD Continuous infusion         506.83               80.70          105.00             77                        65.25                   13                       441.58
  Imipenem BD Continuous infusion         193.16               52.40          37.00              86                        16.67                   9                        176.49
  Doripenem HD                            150.38               90.1           102.00             84                        77.20                   51                       73.18
  Doripenem BD                            144.33               75.60          32.00              80                        19.35                   13                       124.98
  Ceftriaxone HD                          141.65               49.60          86.58              88                        37.79                   27                       103.86
  Ceftriaxone BD                          80.25                64.60          35.24              79                        17.98                   22                       62.27
  Pipéracillin HD Intermittent infusion   122.52               96.70          103.05             88                        87.69                   72                       34.83
  Pipéracillin BD Intermittent infusion   147.63               92.56          35.50              82                        29.94                   18                       117.69
  Pipéracillin HD Continuous infusion     90.48                70.50          98.50              86                        59.72                   66                       30.76
  Pipéracillin BD Continuous infusion     42.74                80.10          30.00              80                        19.22                   45                       23.52
  Ofloxacin HD                            56.93                59.50          102.00             86                        52.19                   92                       49.44
  Ofloxacin BD                            68.18                66.00          35.50              80                        18.74                   28                       4.74
  Linezolid HD                            84.94                76.20          102.00             77                        59.84                   70.50                    55.48
  Linezolid BD                            77.26                80.50          33.00              82                        21.78                   28                       25.10
  Daptomycin HD                           27.42                12.50          105.00             88                        11.55                   42                       15.87
  Daptomycin BD                           17.11                15.80          37.00              85                        4.97                    29                       12.14
  Metronidazole HD                        59.09                82.10          92.00              78                        58.91                   100                      19.78
  Metronidazole BD                        61.22                89.30          37.00              80                        26.43                   43                       0.18
  Fluconazole HD                          29.35                59.20          85.00              80                        26.05                   89                       14.79
  Fluconazole BD                          34.57                75.40          32.00              82                        19.78                   57                       0.30
  Voriconazole BD                         105.31               40.50          35.00              88                        12.47                   12                       92.84

CL~CVVH~ = C~s~ × Q~UF~ × dilution factor = convection clearance; dilution factor = Q~blood~/(Q~blood~ + Q~inf~); Q~inf~ is the infusion rate of the substitution fluid; CL~S~ = total body clearance; C~S~ = Sieving coefficient = 2 × CUF / (Cpre + Cpost); CUF = the drug concentration in ultrafiltrate; Cpre = the drug concentration in prefilter serum corrected for predilution; Cpost = the drug concentration in postfilter serum; *n* = number of patients; CL~NR~ = non renal clearance = CLS - CLCVVH.

###### 

PK/PD parameters for all studied antibiotics

  **Antibiotic**                  **Isolated Pathogen**          **MIC (µg/mL)**   **T% \> MIC**   **IQ = Cmax/CMI or Css/CMI**
  ------------------------------- ------------------------------ ----------------- --------------- ------------------------------
  **Imipenem**                    *Pseudomonas aeruginosa* (1)   3                 34              4
  *Escherichia coli* (1)          1                              57                11              
  *Enterococcus faecalis* (1)     3                              37                4               
  *Streptococcus sp.* (1)         2                              57                9               
  *Klebsiella pneumoniae* (1)     0.5                            85                23              
  *Pseudomonas aeruginosa* (2)    1                              43                13              
  *Enterobacter cloacae* (1)      2                              65                6               
  **Ofloxacin**                   *Klebsiella oxytoca* (1)       0.3               \-              17
  *Moraxella catarrhalis* (1)     0,25                           \-                22              
  *Enterobacter cloacae*(2)       0,25                           \-                46              
  *Moraxella catarrhalis* (2)     0.3                            \-                36              
  *Pseudomonas aeruginosa* (3)    2                              \-                5               
  *Escherichia coli* (3)          1                              \-                6               
  *Serratia sp.*                  1                              \-                6               
  **Piperacillin**                *Enterobacter cloacae* (3)     3                 100             11
  *Stenotrophomonas maltophila*   12.5                           84                10              
  *Streptococcus sp.* (2)         0,05                           100               700             
  *Escherichia coli* (4)          1                              100               49              
  *Acinetobacter baumanii* (1)    9                              100               4               
  *Enterobacter cloacae* (4)      3                              100               11              
  *Klebsiella oxytoca* (2)        14                             100               9               
  *Pseudomonas aeruginosa* (4)    2                              100               20              
  *Escherichia coli* (5)          26                             58                5               
  *Proteus mirabilis*             0,06                           100               583             
  *Acinetobacter baumanii* (2)    4                              80                9               
  *Escherichia coli* (6)          0.2                            100               159             
  *Streptococcus haemolysis*      0,05                           65                10              
  *Enterobacter aerogenes* (1)    1                              100               49              
  **Ceftriaxone**                 *Escherichia coli* (7)         0,02              100             10000
  *Enterococcus faecalis* (4)     6                              48                35              
  *Escherichia coli* (8)          0,02                           83                10000           
  *Enterococcus faecalis* (5)     0.3                            58                588             
  **Ertapenem**                   *Klebsiella oxytoca* (3)       0,2               100             50
  *Enterobacter cloacae* (5)      0,1                            100               100             
  *Escherichia coli* (9)          0.5                            80                200             
  *Enterobacter cloacae* (6)      1                              90                100             
  *Klebsiella oxytoca* (4)        0.5                            90                200             
  *Enterobacter cloacae* (7)      1                              78                100             
  *Klebsiella oxytoca* (5)        0,06                           100               1667            
  **Linezolid**                   *Staphylococcus aureus* (1)    2.50              32              8
  *Staphylococcus aureus* (2)     1                              90                20              
  *Staphylococcus aureus* (3)     0.5                            80                40              
  **Doripenem**                   *Enterobacter cloacae* (8)     1                                 12
  *Enterobacter aerogenes* (2)    0,03                           100               375             
  *Acinetobacter baumanii* (3)    2                              88                6               
  *Pseudomonas aeruginosa* (5)    1                              100               12              
  *Pseudomonas aeruginosa* (6)    2                              100               6               
  *Pseudomonas aeruginosa* (7)    1                              100               12              
  *Enterococcus faecalis* (6)     1.5                            80                9               
  **Daptomycin**                  *Staphylococcus aureus* (4)    0.5               100             110
  *Staphylococcus aureus* (5)     1                              90                55              
  *Enterococcus faecalis* (2)     1                              88                55              
  *Enterococcus faecalis* (3)     1                              70                55              
  **Metronidazole**               *Bacterioides fragilis* (1)    0.5               90              20
  *Bacterioides fragilis* (2)     0.5                            90                20              

DISCUSSION {#j_jtim-2019-0031_s_004}
==========

Antimicrobial clearance during CRRT is determined by several chemical drug characteristics.^\[[@j_jtim-2019-0031_ref_017]\]^ Molecular weight and drug solubility are no limiting factors since antimicrobials are mostly small hydrophilic molecules.^\[[@j_jtim-2019-0031_ref_018],[@j_jtim-2019-0031_ref_019]\]^ Drug Vd may increase significantly during resuscitation of septic shock. Thus, extracellular water and by extension current body weight must be considered to optimize the dose of certain antibiotic classes (*e.g.*, aminoglycosides).^\[[@j_jtim-2019-0031_ref_020]\]^ Protein binding remains the most important factor limiting antimicrobial elimination by convective CRRT.^\[[@j_jtim-2019-0031_ref_021]\]^ Protein-bound molecules do not pass the pores of the currently used dialysis membranes. However, protein binding in critically ill patients may be highly variable. An increase in unbound drug will increase Sc and Sd, and hence, clearance by CRRT.^\[[@j_jtim-2019-0031_ref_022]\]^ Based on the aforementioned, antimicrobial drugs can be categorized as "highly", "moderately" or "not at all" eliminated by CRRT.

Antimicrobial agents have three "killing profiles": time-dependent, concentration-dependent, or a combination of both. These profiles determine the drug dosing to obtain maximum therapeutic efficacy at minimal risk for the development of resistance and toxicity.^\[[@j_jtim-2019-0031_ref_023]\]^ CL~NR~ was significantly higher for all agents during HV-CVVH as compared with SV-CVVH, which is somewhat unexpected because of the augmented CL~CVVH~ in the HV-CVVH group.

Drugs highly influenced by CRRT {#j_jtim-2019-0031_s_004_s_001}
-------------------------------

### Time-dependent killing {#j_jtim-2019-0031_s_004_s_001_s_001}

The β-lactams (penicillins, cephalosporins, carbapenems and monobactams) are small hydrophilic molecules and thus likely to be significantly cleared by CRRT. They exhibit time-dependent killing and have a slow continuous bactericidal effect. Killing is most related to the time during which serum concentration exceeds 1 to 5 times the MIC and, in part, also to a continued suppression of bacterial growth even when drug concentrations fall below MIC (*i.e.*, the post-antibiotic effect).^\[[@j_jtim-2019-0031_ref_024]\]^ To obtain maximal bactericidal activity, a T \> MIC of 50 to 60% is required for penicillins and monobactams, 60 to 70% for cephalosporins and 40% for carbapenems.

Piperacillin-tazobactam {#j_jtim-2019-0031_s_004_s_002}
-----------------------

Mueller *et al*. investigated the PK of piperacillin-tazobactam in anuric patients treated with CVVHD. The elimination half-life of piperacillin was 4.3 ± 1.2 h, and that of tazobactam 5.6 ± 1.3 h. The contribution of CVVHD to the overall elimination was relevant (\> 25%) for both drugs.^\[[@j_jtim-2019-0031_ref_025]\]^ A recent study in critically ill patients on CVVHDF receiving piperacillin-tazobactam (4 g/0.5 g) every 8 h showed a total clearance of 5.1 (4.2--6.2) L/h and 3.8 (3.3--4.2) L/h and a CVVHDF clearance of 2.5 (2.3--3.1) L/h and 2.5 (2.3--3.2) L/h for piperacillin and tazobactam, respectively.^\[[@j_jtim-2019-0031_ref_026]\]^ In patients treated with CVVHDF and receiving a 4 h infusion of piperacillin 4 g / tazobactam 0.5 g every 8 h, Awissi *et al*. found a median total clearance of 65.82 mL/min (53.79--102.87), and a median renal clearance of 0.16 mL/min (0.05--3.04). Median CRRT dose was 32.0 mL/kg/h (25.0--39.8).^\[[@j_jtim-2019-0031_ref_027]\]^ Although some studies suggest a better outcome in critically ill patients receiving prolonged infusion, the level of evidence is moderate.^\[[@j_jtim-2019-0031_ref_028]\]^ In our study, the *in vivo* concentration obtained after a daily high dose (16 g) continuous but not bolus infusion of piperacillin was adequate, stable throughout time, and within the recommended range for efficacy even in HVCVVH treated patients. This underscores that piperacillin treatment during CRRT is most efficacious when administered as a loading dose followed by continuous infusion especially at MIC values of 16 to 32 mg/L.^\[[@j_jtim-2019-0031_ref_029]\]^

Imipenem {#j_jtim-2019-0031_s_004_s_003}
--------

Fish *et al*. studied the PK of imipenem during CVVH and continuous veno-venous hemodiafiltration (CVVHDF). Mean CLs and elimination half-life (t1/2) of imipenem were 145 ± 18 mL/min and 2.7 ± 1.3 h during CVVH and 178 ± 18 mL/min and 2.6 ± 1.6 h during CVVHDF, respectively. Imipenem clearance was substantially increased during both CVVH and CVVHDF, with membrane clearance representing respectively 25% and 32% of CLs.^\[[@j_jtim-2019-0031_ref_030]\]^ We found mean imipenem SC, CL~CVVH~ and t~1/2~ ranging from 52.40 to 80.70%, 16.67 to 65.25 mL/min, and 1.29 to 1.51 h respectively. Total clearances were higher than previously published (158.82 to 506.83 mL/min) with membrane clearance ranging from 9% to 18%. ^\[[@j_jtim-2019-0031_ref_031]\]^

Ertapenem and doripenem {#j_jtim-2019-0031_s_004_s_004}
-----------------------

The newer carbapenems ertapenem and doripenem are more stable after reconstitution and have a longer t1/2. Mistry *et al*. showed that hemodialysis cleared approximately 30% of the ertapenem dose.^\[[@j_jtim-2019-0031_ref_032]\]^ Hidaka *et al*. showed that total body clearance of doripenem was 58.0 ± 12.7 mL/min, including 13.5 ± 1.6 mL/min CVVHDF clearance. Mean t1/2 of doripenem was 7.9 ± 3.7 h. Thus, under the conditions tested, CVVHDF appeared to have little effect on doripenem clearance. Therefore, serum levels of doripenem during CVVHDF can be controlled by adjustment of dose and dosing interval in accordance with residual renal function.^\[[@j_jtim-2019-0031_ref_033]\]^ Cirillo *et al*. showed that both CVVH and CVVHD efficiently removed doripenem with an SC of respectively 67% and 76%.^\[[@j_jtim-2019-0031_ref_034]\]^ We demonstrated that, despite acceptable *in vivo* concentrations of ertapenem or doripenem after bolus or continuous infusion, a prolonged (4 h) bolus or continuous infusion may be beneficial to keep concentrations longer above MIC. From our study, it can be concluded that imipenem should be replaced by doripenem or meropenem during CRRT. A higher meropenem dose (*i.e.*, 3000 to 6000 mg), may be most adequate whilst preventing resistance of pathogens with MICs between 4 and 8 µg/mL, in particular, *Pseudomonas aeruginosa* strains. Continuous infusion of meropenem preferred mode because the drug is stable for 8 h.^\[[@j_jtim-2019-0031_ref_035]\]^

### Linezolid {#j_jtim-2019-0031_s_004_s_004_s_001}

Meyer *et al*. showed that linezolid PK during CVVH was comparable to that of healthy subjects and patients without renal impairment. The t1/2, total clearance and hemofiltration clearance were 4.3 ± 1.7 h, 9.3 ± 3.5 L/h and 1.9 ± 0.8 L/h, respectively.^\[[@j_jtim-2019-0031_ref_036]\]^ Pea *et al*. identified significant elimination of linezolid in patients undergoing CVVH. Total clearance was 25% higher and serum trough concentration 50% lower. In 93% of the patients, serum concentrations above MIC were obtained after the administration of a standard dose (600 mg every 12 h) of linezolid. However, the mean *T%* MIC was only 57% of the dosing interval for pathogens with a MIC of 4 mg/L. Thus, 600 mg of linezolid every 8 h may be necessary to assure optimal antibacterial activity.^\[[@j_jtim-2019-0031_ref_037]\]^

We suggest that, whenever possible, time-dependent antibiotics should be administered in continuous infusion during CRRT. As the risk of overdosing is limited and to avoid underdosing, higher than currently recommended doses should be prescribed, particularly when the range of therapeutic concentrations is large.^\[[@j_jtim-2019-0031_ref_019]\]^

Drugs moderately influenced by CRRT (or when CVVH clearance largely contributes to total body clearance in AKI)

In this category, antibiotic clearance is close to normal clearance in patients without AKI. Standard doses may be sufficient for optimal treatment.

Concentration-dependent killing {#j_jtim-2019-0031_s_004_s_005}
-------------------------------

### Metronidazole {#j_jtim-2019-0031_s_004_s_005_s_001}

In patients undergoing dialysis, plasma t~1/2~ of metronidazole was 6.8 h, which is comparable with healthy subjects. Dialysis clearance of metronidazole was 60 mL/min with 25% drug eliminated at the start of treatment.^\[[@j_jtim-2019-0031_ref_038]\]^ Kreeft *et al*. found that plasma metronidazole concentrations in patients with renal insufficiency were similar to those in patients with normal renal function. Moreover, renal insufficiency did not affect beta half-life (6.5 h) or plasma clearance (10.1 L/h) of metronidazole.^\[[@j_jtim-2019-0031_ref_039]\]^ In our study, mean metronidazole SC, CL~CVVH~ and t~1/2~ ranged from 82.10 to 89.30%, 26.43 to 58.91 mL/min, and 8.22 to 10.18 h respectively. Accordingly, a dose of 1500 mg once daily is proposed. The currently prescribed dose of 500 mg three times daily should be abandoned!

### Ofloxacin {#j_jtim-2019-0031_s_004_s_005_s_002}

During CVVH, Fuhrmann *et al*. found a mean serum ofloxacin concentration peak of 5.5 ± 0.7 mg/L and a t1/2, hemofiltration clearance, and total removal of 2.8 ± 0.5 h, 89.9 ± 4.5 mL/min, and 76.9% ± 7.1%, respectively.^\[[@j_jtim-2019-0031_ref_040]\]^ In our study, mean ofloxacin SC, CL~CVVH~ and t1/2 ranged from 59.50 to 66.00%; 18.74 to 52.19 mL/min and 6.58 to 8.72 h, respectively. However, due to the high volume of distribution, serum concentration is comparable between the standard and high volume group, implying that no dose adaptation is required at increasing CVVH dose. Choi *et al*. ^\[[@j_jtim-2019-0031_ref_041]\]^ studied levofloxacin in an *in vitro* CVVH model and found significantly less drug adsorption on a polyamide than on a polyacrylonitrile (PAN) filter. Polyethersulfone used in our study has a pretty bad record regarding almost no drug adsorption.^\[[@j_jtim-2019-0031_ref_042]\]^ Post-dilution resulted in a small but statistically significant decrease in SC when a PAN filter was used.

Time-dependent killing {#j_jtim-2019-0031_s_004_s_006}
----------------------

### Fluconazole {#j_jtim-2019-0031_s_004_s_006_s_001}

Fluconazole has a low protein binding and a low molecular weight. About 80% is eliminated unchanged by the kidneys. Fluconazole is effectively cleared by hemodialysis and hemofiltration.^\[[@j_jtim-2019-0031_ref_043]--[@j_jtim-2019-0031_ref_044]\]^ Pittrow and Penk showed that patients undergoing CRRT require a similar loading dose of fluconazole as patients with normal renal function. Thereafter, a maintenance dose is given adjusted for anuria by multiplying with a factor accounting for extracorporeal elimination of the absorbed dose.^\[[@j_jtim-2019-0031_ref_045]\]^ Yagasaki *et al*. found that continuous hemodiafiltration is highly effective for fluconazole removal. Fluconazole should be administered at a dose of 500 to 600 mg every 12 h ^\[[@j_jtim-2019-0031_ref_046]\]^ but close hepatic, neurological, and ECG (QT interval!) monitoring is mandatory. Bergner *et al*. measured plasma fluconazole concentrations during CVVHDF.^\[[@j_jtim-2019-0031_ref_046]\]^ All patients reached levels between 16 and 32 mg/L, which remained in this range for minimal 1 and up to 24 h (on average 9.6 h at an UF rate of 2000 mL/h and 15.7 h at an UF rate of 1000 mL/h). Thus, a once-daily dose of 800 mg fluconazole is necessary to achieve optimal fungicidal activity.^\[[@j_jtim-2019-0031_ref_047]\]^ CVVH effectively removes fluconazole from the circulation by a clearance into the hemofiltrate of approximately 21 mL/min. This implies no dose reduction during CVVH.^\[[@j_jtim-2019-0031_ref_048]\]^ Muhl *et al*. compared the elimination of fluconazole during continuous veno-venous hemodialysis (CVVHD) and CVVH at different dosages. Extracorporeal clearance (CVVHD 30.5 mL/min, CVVH 17.5 mL/min) and total clearance of fluconazole (CVVHD 37.9 mL/min, CVVH 25.3 mL/min) were significantly higher during CVVHD. During CVVHD, the sieving coefficient (S) (CVVHD) was 0.88 and t1/2 was 14.8--35.1 h. During CVVH, the S(CVVH) was 0.96 and t1/2 was 24.0--51.6 h. Since CVVHD clearance may considerably exceed the clearance in patients with normal renal function, a daily dose of 400 to 800 mg is recommended during CVVHD.^\[[@j_jtim-2019-0031_ref_049]\]^ In our study, mean fluconazole SC, CL~CVVH~ and t1/2 ranged from 59.20 to 75.40%, 19.78 to 26.05 mL/min, and 28.54 to 33.85 h, respectively. Taken together, fluconazole should be administered at a dose of 500 to 600 mg every 12 h.^\[[@j_jtim-2019-0031_ref_046]\]^ Point of care dosing of fluconazole could be an interesting option.^\[[@j_jtim-2019-0031_ref_050]\]^

Drugs not influenced by CRRT {#j_jtim-2019-0031_s_004_s_007}
----------------------------

### Time dependent killing Ceftriaxone {#j_jtim-2019-0031_s_004_s_007_s_001}

Ceftriaxone clearance in patients receiving CVVHD is equivalent to clearance in subjects with normal renal function. Therefore, no dose adjustment is necessary.^\[[@j_jtim-2019-0031_ref_051],[@j_jtim-2019-0031_ref_052]\]^ In hemodialyzed patients, administration of 2 g ceftriaxone resulted in a T \> MIC of 88.5 (78.8--98.3) h and 17.7 (13.3--22.0) h for MIC breakpoints of 1 and 8 mg/L, respectively.^\[[@j_jtim-2019-0031_ref_053]\]^ See comment in PubMed Commons belowIn patients with various degrees of renal impairment, Patel *et al*. confirmed the PK efficacy of a 2 g ceftriaxone dose. T1/2 (group mean ranged from 11.7 to 17.3 h) and plasma clearance (group mean ranged from 529 to 705 ml/h) showed no correlation with creatinine clearance.^\[[@j_jtim-2019-0031_ref_054]\]^ In our study, mean ceftriaxone SC, CLCVVH and t1/2 ranged from 49.60 to 64.60%, 17.98 to 37.79 mL/min and 4.19 to 5.76 h, respectively.

Concentration dependent killing {#j_jtim-2019-0031_s_004_s_008}
-------------------------------

### Daptomycin {#j_jtim-2019-0031_s_004_s_008_s_001}

Salama *et al*. obtained sufficient pre-hemodialysis serum concentrations after thrice-weekly post-hemodialysis administration of 6 mg/kg daptomycin even after a 68 h interval between dialysis sessions.^\[[@j_jtim-2019-0031_ref_055]\]^ Mean urea and daptomycin reduction ratios were 79.6 ± 5.8% and 57.6 ± 9.2%, respectively. Daptomycin half-life was 19.4 ± 6.5 and 3.8 ± 1.1 h "off" and "on" hemodialysis, respectively, with minimal rebound 1 h post-hemodialysis. Churchwell *et al*. studied transmembrane clearance of daptomycin during CVVH and CVVHD in an *in vitro* model that employed AN69 and polysulfone hemodiafilters at varying ultrafiltrate and dialysate flow rates. Clearance depended on filter type and dialysate and ultrafiltration rates. High ultrafiltrate or dialysate rates resulted in substantial daptomycin clearance.^\[[@j_jtim-2019-0031_ref_056]\]^ Corti *et al*. found no significant accumulation of daptomycin when a dose of 6 mg/kg was given to patients undergoing CRRT with an effluent flow rate \> 30 mL/kg/h.^\[[@j_jtim-2019-0031_ref_057]\]^ In our study, mean daptomycin SC, CL~CVVH~ and t1/2 ranged from 12.50 to 15.80%, 4.97 to 11.55 mL/min and 8.53 to 11.94 h, respectively.

### Voriconazole {#j_jtim-2019-0031_s_004_s_008_s_002}

Being poorly water-soluble, the intravenous voriconazole formulation includes the vehicle sulfobutylether-beta-cyclodextrin sodium (SBECD). SBECD is not protein-bound and predominantly eliminated by glomerular filtration. Intravenous voriconazole is not recommended in patients with a creatinine clearance \< 50 mL/min because of potentially toxic accumulation of SBECD.^\[[@j_jtim-2019-0031_ref_058]\]^ Tyree *et al*. recently showed that CVVH effectively removed SBECD at a rate similar to the ultrafiltration rate.^\[[@j_jtim-2019-0031_ref_059]\]^ Voriconazole clearance by CVVH was not clinically significant. Standard doses of intravenous voriconazole can be used safely in patients undergoing CVVH. Quintard *et al*. studied voriconazole PK during HV-CVVH. See comment in PubMed Commons belowThe total body clearance of voriconazole was 5.4 L/h with a half-life of 16.5 h and a distribution volume of 128.6 L. The estimated SC was 0.58 and the filtration clearance 1.39 L/h. HV-CVVH may affect voriconazole disposition more than other techniques.^\[[@j_jtim-2019-0031_ref_060],[@j_jtim-2019-0031_ref_061]\]^ When voriconazole doses mount to 6 mg/kg per 12 h, intermittent hemodialysis may fail to completely eliminate SBECD. CRRT is then recommended to avoid vehicle-induced toxicity.^\[[@j_jtim-2019-0031_ref_061],[@j_jtim-2019-0031_ref_062]\]^

STUDY LIMITATIONS {#j_jtim-2019-0031_s_005}
=================

The current study has major flaws and limitations. First, therapeutic drug monitoring remained observational and was not applied to improve PK/PD of the studied antimicrobials. Evaluating the impact of many relevant patient- and technique-related variables influencing PK/PD (*i.e.*, distribution volume, membrane type, MIC of the micro-organisms, quality of resuscitation)^\[[@j_jtim-2019-0031_ref_063],[@j_jtim-2019-0031_ref_064],[@j_jtim-2019-0031_ref_065]\]^ also remained beyond the scope of the study. Second, at the time of study, all patients received unfractionated heparin for extracorporeal circuit anticoagulation. Today, regional citrate anticoagulation is increasingly used. Citrate better preserves porosity and adsorptive capacity of the membrane, which inherently results in different antimicrobial elimination.^\[[@j_jtim-2019-0031_ref_064],[@j_jtim-2019-0031_ref_066]\]^ Third, non-adsorptive membranes were used, which have been progressively supplanted by highly adsorptive membranes. The latter more effectively eliminate antimicrobials through bulk rather than surface adsorption.^\[[@j_jtim-2019-0031_ref_064],[@j_jtim-2019-0031_ref_067],[@j_jtim-2019-0031_ref_068]\]^ Finally, data were gathered during HV-CVVH, which did not prove to be superior to SV-CVVH.^\[[@j_jtim-2019-0031_ref_011]\]^

CONCLUSIONS & PERSPECTIVES {#j_jtim-2019-0031_s_006}
==========================

As expected, HV-CVVH eliminated more antibiotics than SV-CVVH. All agents were easily filtered. Mean elimination t1/2 of all agents was significantly shorter during HVCVVH than during SV-CVVH. CLs, CL~CVVH~, and CL~NR~ of all agents were significantly higher during HV-CVVH.

Antibiotics that are highly removed by CRRT should be preferentially administered as a continuous infusion. A loading dose of 4 g followed by a continuous infusion of 16 g provides the most optimal PK for piperacillin. Regarding carbapenems, our results argue against the use of imipenem during CRRT. Doripenem or meropenem are better options. A meropenem dose of 3 to 6 g is required to adequately treat pathogens with MICs between 4 to 8 mg/L, especially *Pseudomonas aeruginosa* strains. As meropenem was found to be stable for 8 h, it can be given as a continuous perfusion. In almost all patients, linezolid concentrations above the MIC were obtained after administration of a standard dose (600 mg every 12 h) but optimal antibacterial activity at a MIC of 4 mg/L requires 600 mg linezolid every 8 h.

During CRRT, the "classical" 500 mg three times daily metronidazole dose should be abandoned and replaced by **a** 1500 mg once daily dose. The dose of fluconazole must be increased to 500 to 600 mg every 12 h. When higher doses of voriconazole (up to 6 mg/kg per 12 h) are needed, intermittent hemodialysis should be replaced by CRRT to avoid toxicity induced by the SBECD vehicle.

CRRT significantly influences the PK/PD behavior of most antimicrobial agents. This is insufficiently anticipated by the current dosing guidelines. Patients are particularly at risk for underdosing, which may cause treatment failure and enhance resistance. [Table 5](#j_jtim-2019-0031_tab_005){ref-type="table"} depicts dose recommendations for some major antibiotic and antifungal drugs during CVVH (at a dose of 25 mL/kg/h) that are based upon relevant literature data ^\[[@j_jtim-2019-0031_ref_069],[@j_jtim-2019-0031_ref_070],[@j_jtim-2019-0031_ref_071],[@j_jtim-2019-0031_ref_072],[@j_jtim-2019-0031_ref_073],[@j_jtim-2019-0031_ref_074],[@j_jtim-2019-0031_ref_075],[@j_jtim-2019-0031_ref_076],[@j_jtim-2019-0031_ref_077]\]^ and our own findings.

###### 

Dose recommendations for some frequently used antimicrobials during CRRT (CVVH, 25 mL/kg/h)

  **Antimicrobial**         **Loading dose**         **Maintenance dose**
  ------------------------- ------------------------ ------------------------------
  Amikacin                  30-35 mg/kg              TDM
  Meropenem                 2 g                      2 g over 3 h tid
  Piperacillin-tazobactam   4 g/0.5 g                16 g/2 g (CI)
  Vancomycin                35 mg/kg over 4 h        30 mg/kg (TDM = 25--30 mg/L)
  Teicoplanin               15 mg/kg bid             600 mg od
  Linezolid                                          600 mg tid
  Ciprofloxacin             800 mg                   400 mg tid
  Tigecyclin                150 mg                   100 mg bid
  Colistin                  9 MIU                    4.5 MIU tid
  Voriconazole              8 mg/kg bid              6 mg/kg bid
  Fluconazole                                        600 mg bid
  Cefepime                                           2 g tid
  Gentamycin                                         7 mg/kg od
  Bactrim                   1200 mg/240 mg (3 amp)   800 mg/160 mg (2 amp) tid
  Clindamycin                                        900 mg qid

TDM = therapeutic drug monitoring; od = once daily; bid = twice daily; tid = three times daily; qid = four times daily; amp = ampules; CI = continuous infusion; MIU = million units. According to references No. 68--77 -- Adapted and changed from reference No. 63.
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